No Data
No Data
Gossamer Bio Management to Meet With Oppenhiemer
Bullish Outlook on Gossamer Bio's Seralutinib Efficacy and Market Potential
Oppenheimer Maintains Gossamer Bio(GOSS.US) With Buy Rating, Raises Target Price to $9
Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Gossamer Bio Announced Two Oral Presentations And Poster Presentation With Data Relevant To Seralutinib At European Respiratory Society Congress 2024
Analysts Just Made A Notable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Forecasts
loading...
Rockhoundj : Whaddya think about FRGT$Freight Technologies (FRGT.US)$ ?
FattyChick OP Rockhoundj : From the last RS earlier this year, the next RS coming soon
FattyChick OP Rockhoundj : If you really want to get a position, entry 0.108 - 0.11.
TP 0.136.
Rockhoundj FattyChick OP : I’m holding just under .13
With a tight stop loss
Jenna Ragan : these look nice
View more comments...